Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 43Breast Neoplasms 37Lymphoma, Large B-Cell, Diffuse 29Sarcoma 20Lymphoma, Non-Hodgkin 17Burkitt Lymphoma 16Neuroblastoma 15Leukemia 13HIV Infections 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Hodgkin Disease 11Acquired Immunodeficiency Syndrome 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Ovarian Neoplasms 9Multiple Myeloma 9Carcinoma, Hepatocellular 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Liver Neoplasms 8Liposarcoma 7Breast Neoplasms, Male 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Anaplastic 6Fallopian Tube Neoplasms 6Sarcoma, Kaposi 5Neoplasms, Plasma Cell 5Lymphoma, B-Cell 5Lung Neoplasms 5Histiocytoma, Malignant Fibrous 5Fibrosarcoma 5

Interventions

siplizumab 1liposomal doxorubicin 1Vincristine 1Rituximab 1Prednisone 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Subcutaneous panniculitis-like T-cell lymphoma × Doxorubicin × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡